-transparent.png){kind=logo}
Treatment with indomethacin, aspirin, or prednisone has been shown to reduce urinary fibrin/fibrinogen degradation products (F.D.P.) in approximately two-thirds of patients with proliferative glomerulonephritis. This reduction which is dose-dependent for prednisone but not for indomethacin or aspirin in the range of doses used occurs within two to three days of beginning treatment and is thought to result from decreased intraglomerular fibrin deposition rather than alteration of glomerular permeability to F.D.P. In patients who responded in this manner treatment was associated with reductions in the degree of proteinuria and maintenance or improvement in renal function.
Related Publications
A R Clarkson, and
M K MacDonald, and
J D Cash, and
J S Robson
January 1974,
Acta medica Scandinavica,
A R Clarkson, and
M K MacDonald, and
J D Cash, and
J S Robson
April 1975,
British medical journal,
A R Clarkson, and
M K MacDonald, and
J D Cash, and
J S Robson
September 1986,
Fukuoka igaku zasshi = Hukuoka acta medica,
A R Clarkson, and
M K MacDonald, and
J D Cash, and
J S Robson
September 1971,
British medical journal,
A R Clarkson, and
M K MacDonald, and
J D Cash, and
J S Robson
January 1978,
Nihon Jinzo Gakkai shi,
A R Clarkson, and
M K MacDonald, and
J D Cash, and
J S Robson
September 1976,
Scandinavian journal of clinical and laboratory investigation,
A R Clarkson, and
M K MacDonald, and
J D Cash, and
J S Robson
February 1975,
British medical journal,
A R Clarkson, and
M K MacDonald, and
J D Cash, and
J S Robson
February 1981,
Thrombosis research,
A R Clarkson, and
M K MacDonald, and
J D Cash, and
J S Robson
April 1978,
Nihon Jinzo Gakkai shi,
A R Clarkson, and
M K MacDonald, and
J D Cash, and
J S Robson
January 1993,
Nihon Jinzo Gakkai shi,
